Overview


According to FutureWise analysis, the market for Acute Spinal Cord Injury is expected to grow at a CAGR of 5.60% over the forecast period of 2023-2031.

Acute spinal cord injury (SCI) results from traumatic damage to the spinal cord, which can involve bruising and partial or complete tears. It is a significant cause of permanent disability and mortality, affecting children and adults. Various arrays of factors can lead to acute SCI, with common causes including falls, motor vehicle accidents (involving cars, motorcycles, or pedestrians), sports-related injuries, diving accidents, trampoline accidents, violence (such as gunshot or stab wounds), infections that form abscesses on the spinal cord, and birth injuries that typically affect the neck area of the spinal cord. On the basis of the location and severity of the injury, symptoms of acute SCI can vary. Initial symptoms often include losing or decreasing feeling, muscle movement, and reflexes due to spinal shock. As swelling subsides, additional symptoms may emerge based on the injury's location. The extent of spinal cord damage determines whether the injury is complete (no feeling or movement below the injury level) or incomplete (some degree of texture or movement below the injury level). 

Diagnosing acute SCI is a medical emergency; immediate evaluation is necessary when a spinal cord injury is suspected. The diagnosis begins with a physical examination and is followed by various diagnostic tests, including blood tests, computed tomography (CT) scans, and magnetic resonance imaging (MRI) X-rays, to assess the extent of the injury. In some cases, surgery may be required to stabilize the spinal cord. Treatment for acute SCI includes medical management, medications like corticosteroids to reduce swelling, mechanical ventilation to assist breathing, and interventions like bladder catheters and feeding tubes. Recovery from SCI often necessitates extended hospitalization and rehabilitation, involving a team of healthcare professionals to manage pain, monitor vital functions, and address various aspects of patient care. While preventing SCI entirely may not be guaranteed, preventive measures can help reduce the risk. These measures include not driving under the influence of alcohol or drugs, consistently wearing seat belts in vehicles, taking precautions to prevent falls at home, securing firearms safely, and using helmets during activities that may lead to head injuries, such as motorcycle riding and sports participation (e.g., biking, skiing, hockey, football).

FutureWise Market Research has published a report that provides an insightful analysis of Acute Spinal Cord Injury Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts’ projects that Acute Spinal Cord Injury Market will experience a significant growth.

According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Novartis AG
  • Tenax Therapeutics
  • Accure Pharma
  • Acorda Therapeutics, Inc.
  • ReNetX Bio
  • BioArctic AB
  • BioTime, Inc.
  • InVivo Therapeutics
  • Kringle Pharma, Inc.
  • BioAxone
  • AO Foundation
  • Pfizer Inc.
  • Pharmicell Co. Ltd.
  • Vertex Pharmaceuticals Inc.
  • Axoltis
  • K-STEMCELL Co., Ltd.
  • WAKAYAMA MEDICAL UNIVERSITY

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Development in Acute Spinal Cord Injury Market: 

  • Amneal Pharmaceuticals, Inc. disclosed its plan to commence the commercial availability of LYVISPAH, an FDA-approved specialty product containing baclofen oral granules in 5 mg, 10 mg, and 20 mg doses, specifically designed for addressing spasticity associated with multiple sclerosis and other spinal cord disorders was launched in June 2022.

Increasing awareness of spinal cord injuries among the general public and healthcare professionals is the primary driver for market growth. This heightened awareness has led to quicker diagnoses and a greater emphasis on early interventions, potentially improving patient outcomes. Advanced medical technologies and treatment modalities also serve as important drivers. Innovations such as stem cell therapies, neurorehabilitation techniques, and spinal cord implants are at the forefront of research and development, offering hope for improved treatments and recovery options for patients. Rising healthcare expenditure in many regions, particularly in developed countries, contributes to the growth of this market. Increased funding and investments in spinal cord injury research and care facilities further support the development of new therapies and approaches. However, the acute spinal cord injury market faces significant restraints. High treatment costs, particularly for cutting-edge therapies and long-term rehabilitation, can hinder access for many patients. Inadequate healthcare infrastructure in certain regions, especially in low-income areas, limits specialized care and treatment options availability. The complexity of treatment for spinal cord injuries and their diverse presentations makes addressing these injuries particularly challenging. Regulatory hurdles, including the stringent approval processes for new treatments, can delay the introduction of potentially beneficial therapies. Furthermore, the long-term and often lifelong nature of spinal cord injury care places substantial demands on healthcare systems, impacting resource allocation and overall healthcare costs.

By Type

  • Laboratory Tests
  • Imaging Tests

By Treatment Type

  • Corticosteroid
  • Surgery
  • Spinal Traction

By End User

  • Hospitals
  • Trauma Centers

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process. 

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America is dominant in the acute spinal cord injury market, as the region has increased awareness and the adoption of advanced technologies. Also, the major population after COVID-19 prefer working from home and the continuous sitting practise is initiating more spinal cord problems which is again driving the market in the North American region. The Asia-Pacific region is anticipated to experience substantial growth during the forecast period. This growth can be attributed to emerging economies like China, India, and Brazil and increased regional development investments.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the of Acute Spinal Cord Injury Market By Type, By Treatment Type, By End User, By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represents in format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. 
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

 

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Acute Spinal Cord Injury Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Acute Spinal Cord Injury Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Acute Spinal Cord Injury Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Acute Spinal Cord Injury Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Laboratory Tests
        2. Imaging Tests

  • 8.   Acute Spinal Cord Injury Market, By Treatment Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Corticosteroid
        2. Surgery
        3. Spinal Traction

  • 9.   Acute Spinal Cord Injury Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Trauma Centers

  • 10.   North America Acute Spinal Cord Injury Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Acute Spinal Cord Injury Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Acute Spinal Cord Injury Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Acute Spinal Cord Injury Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Acute Spinal Cord Injury Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Novartis AG
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Tenax Therapeutics
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Accure Pharma
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Acorda Therapeutics, Inc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. ReNetX Bio
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. BioArctic AB
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. BioTime, Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. InVivo Therapeutics
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Kringle Pharma, Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. BioAxone
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. AO Foundation
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Pfizer Inc.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Pharmicell Co. Ltd.
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Vertex Pharmaceuticals Inc.
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Axoltis
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. K-STEMCELL Co., Ltd.
          16.1. Company Overview
          16.2. Product Portfolio
          16.3. SWOT Analysis
          16.4. Financial Overview
          16.5. Strategic Overview
        17. WAKAYAMA MEDICAL UNIVERSITY
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client

Related Market

Spinal Cord Trauma Management Market

Read More

Spinal Cord Stimulation System Market

Read More

Spinal Cord Stimulation Devices Market

Read More
Partner

Our Clients